Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Triple-negative Breast Cancer Clinical Trial

— neoMono  

Official title:

An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04770272
• Other study ID #: Phaon1
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 1, 2021
• Est. completion date: August 31, 2024

Study information

• Verified date: January 2024
• Source: Palleos Healthcare GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window to chemotherapy with PDL1-inhibition (Atezolizumab) and identify biomarkers predicting (early) response to or resistance against Atezolizumab (alone and with CTX) allowing patients stratification in future clinical trials

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 416
• Est. completion date: August 31, 2024
• Est. primary completion date: July 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female and male patients, age at diagnosis 18 years and above

• Written informed consent prior to admission to this study

• Histologically confirmed unilateral primary invasive carcinoma of the breast

• Clinical T1c - T4d

• Stage N0-N3 until 21 patients (5%) with stage N3 are randomized, thereafter N0-N2

• Triple negative breast cancer defined by and confirmed by central pathology:

• ER negative (<10% positive cells in IHC) and PR negative (<10% positive cells on IHC)

• HER2 negative breast cancer:

• Either defined by IHC: ICH scores of 0-1 or an ICH score of 2 in combination with a negative in-situ-hybridization (ISH)

• Or defined by ISH: negative ISH

• Identifiable PD-L1 IC-status by central pathology (positive or negative) by means of VENTANA PD-L1 (SP142) assay; positive status is defined by PD-L1 expression on IC on = 1% of the tumor area, negative status is defined by PD-L1 expression on IC on < 1% of the tumor area

• No clinical evidence for distant metastasis (cM0)

• Tumor block available for translational research

• Performance Status Eastern Cooperative Oncology Group (ECOG) = 1 or KI = 80 %

• Negative pregnancy test (urine or serum) within 7 days prior to screening in premenopausal patients

• Women of childbearing potential and male patients with partners of childbearing potential must accept to implement a highly effective (less than 1% failure rate according to Pearl index) including at least one non-hormonal contraceptive measures during the study treatment and for 5 months following the last dose of study treatment such as:

• Intrauterine device (IUD)

• bilateral tubal occlusion

• vasectomized partner

• sexual abstinence

• The patient must be accessible for treatment and follow-up

• Normal cardiac function:

• Normal electrocardiogram (ECG) (within 6 weeks prior to screening)

• Normal left ventricular ejection fraction (LVEF) on echocardiorgaphy

• Normal thyroid function

o Normal TSH and FT4

• Blood counts within 14 days prior screening:

• absolute neutrophile count (ANC) must be = 1,500/mm3

• Platelet count must be = 100,000 / mm3

• Hemoglobin must be = 10 g/dl

• Hepatic functions:

• Total bilirubin must be = 1 upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation > 1 x ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin

• Alkaline phosphatase must be = 2.5 x ULN for the lab

• AST and ALT must be =1.5 x ULN for the lab.

• Patients with AST and ALT or alkaline phosphatase > 1 x ULN are eligible for inclusion if liver imaging (computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET-CT, or PET scan) performed within 3 months prior to randomization (and part of standard of care) does not demonstrate metastatic disease and the requirements in criterion (just above) are met

• Patients with alkaline phosphatase that is > 1 x ULN but less than or equal to 2.5 x ULN or with unexplained bone pain are eligible if bone imaging does not demonstrate metastatic disease.

• Creatinine clearance = 40 ml/min performed 28 days prior to screening

Exclusion Criteria:

• Previous history of malign diseases, non-melanoma skin cancer and carcinoma of the cervix are allowed if treated with curative intent

• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide or Atezolizumab

• Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol

• Concurrent treatment with other drugs that are contraindicating the use of the study drugs

• Existing pregnancy

• Breastfeeding

• Sequential breast cancer

• Concurrent treatment with other experimental drugs and participation in another clinical trial or clinical research project (except registry study) within 30 days prior to study entry

• Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including but not confined to:

• Uncompensated chronic heart failure or systolic dysfunction (LVEF < 55%, congestive heart failure (CHF) New York Heart Association (NYHA) classes II-IV),

• unstable arrhythmias requiring treatment i.e., atrial tachycardia with a heart rate = 100/bpm at rest, significant ventricular arrhythmia (ventricular tachycardia) or highergrade AV-block,

• Angina pectoris within the last 6 months requiring anti-anginal medication,

• Clinically significant valvular heart disease,

• Evidence of myocardial infarction on electrocardiogram (ECG),

• Poorly controlled hypertension (e.g., systolic > 180 mmHg or diastolic > 100 mmHg).

• Inadequate organ function including but not confined to:

• hepatic impairment as defined by bilirubin > 1.5 x ULN

• pulmonary disease (severe dyspnea at rest requiring oxygen therapy)

• Abnormal blood values:

• Platelet count below 100,000/mm3

• AST/ALT > 1.5 x ULN

• Hypokalaemia > CTCAE grade 1

• Neutropenia > CTCAE grade 1

• Anaemia > CTCAE grade 1

• Administration of a live, attenuated vaccine within 4 weeks before cycle 1 day 1 or anticipation that such a vaccine will be required during the study

• Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 28 days or 5 half-lives of the drug, whichever is longer, prior to randomization.

• Treatment with systemic immunosuppressive medications (including but not limited to Prednisone, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis [anti-TNF] factor agents) within 14 days prior to screening or anticipation of need for systemic immunosuppressive medications during the study

• Patients with prior allogeneic stem cell or solid organ transplantation

• Active or history of autoimmune disease or immune deficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:

• Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.

• Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.

• Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are permitted provided all of following conditions are met: Rash must cover < 10% of body surface area; Disease is well controlled at baseline and requires only low-potency topical corticosteroids; No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, Methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral Corticosteroids within the previous 12 months.

• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

• History of HIV infection, hepatitis B or hepatitis C infection.

• Patients with significant cardiovascular disease

• Patients with inadequate hematological and end-organ function

• Patients receiving therapeutic anti-coagulants

• Stage N3, as soon as 21 patients with stage N3 are randomized

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms
• Triple-negative Breast Cancer

Intervention

Drug:
• Atezolizumab 840 MG in 14 ML Injection
840 mg Day 1 for two weeks
• Atezolizumab 1200 MG in 20 ML Injection
1200 mg Day 1 every 3 weeks for 8 cycles
• Carboplatin
Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
• Paclitaxel
Paclitaxel 80 mg/m² IV weekly x 12 cycles
• Epirubicin
90 mg/m2, day 1 for 4 cycles (12 weeks)
• Cyclophosphamide
600 mg/m2, day 1 for 4 cycles (12 weeks)

Procedure:
• Biopsy Arm A
1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
• Biopsy Arm B
1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
• Surgery
After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.

Locations

Country	Name	City	State
Germany	Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;	Bottrop

Sponsors (5)

Lead Sponsor	Collaborator
Palleos Healthcare GmbH	Phaon Scientific GmbH, Roche Pharma AG, University Hospital Erlangen, University Hospital, Essen

Country where clinical trial is conducted

Germany, 

References & Publications (51)

Alme AK, Karir BS, Faltas BM, Drake CG. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol. 2016 Apr;34(4):171-81. doi: 10.1016/j.urolonc.2016.01.006. Epub 2016 Feb 28. — View Citation

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007 May 1;109(9):1721-8. doi: 10.1002/cncr.22618. — View Citation

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Erratum In: Lancet. 2019 Mar 9;393(10175):986. — View Citation

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003. — View Citation

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. doi: 10.1158/1078-0432.CCR-06-3045. — View Citation

Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, Ellsworth RE. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013 Jan;20(1):87-93. doi: 10.1245/s10434-012-2588-8. Epub 2012 Aug 9. — View Citation

Ditsch N, Untch M, Thill M, Muller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kuhn T, Kummel S, Loibl S, Luftner D, Lux MP, Maass N, Mobus V, Muller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schutz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Wenz F, Witzel I, Wockel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel). 2019 Aug;14(4):224-245. doi: 10.1159/000501000. Epub 2019 Aug 6. No abstract available. — View Citation

Dixon JM, Cameron DA, Arthur LM, Axelrod DM, Renshaw L, Thomas JS, Turnbull A, Young O, Loman CA, Jakubowski D, Baehner FL, Singh B. Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. Adv Ther. 2019 Apr;36(4):828-841. doi: 10.1007/s12325-019-0896-0. Epub 2019 Mar 11. — View Citation

Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, Skene T, Evans A, A'Hern R, Iskender A, Wilcox M, Bliss J. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr. 2011;2011(43):120-3. doi: 10.1093/jncimonographs/lgr034. — View Citation

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s. — View Citation

Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, Hood S, Moseley PM, Chan SYT, Pockley AG, Rutella S, McArdle SEB. Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer. Front Immunol. 2018 Sep 11;9:2028. doi: 10.3389/fimmu.2018.02028. eCollection 2018. — View Citation

Gelman A, Stern HS, Carlin JB, Dunson DB, Vehtari A & Rubin DB. Bayesian data analysis. Chapman and Hall/CRC. 2013

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C & Thill M (2019, Dezember 12). Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer. SABCS 2019, Marc.

Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Pare L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int J Cancer. 2020 Jan 1;146(1):262-271. doi: 10.1002/ijc.32488. Epub 2019 Jun 19. — View Citation

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009 Dec;20(12):1913-27. doi: 10.1093/annonc/mdp492. Epub 2009 Nov 9. — View Citation

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258. — View Citation

Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012 Dec;48(18):3342-54. doi: 10.1016/j.ejca.2012.05.023. Epub 2012 Jul 3. — View Citation

Ibrahim JG, Chen MH & Sinha, D. (2014). Bayesian Survival Analysis. In N. Balakrishnan, T. Colton, B. Everitt, W. Piegorsch, F. Ruggeri, & J. L. Teugels (Hrsg.), Wiley StatsRef: Statistics Reference Online (S. stat06003). John Wiley & Sons

Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 1;30(7):729-34. doi: 10.1200/JCO.2011.36.2574. Epub 2012 Jan 30. — View Citation

Keup C, Storbeck M, Hauch S, Hahn P, Sprenger-Haussels M, Tewes M, Mach P, Hoffmann O, Kimmig R, Kasimir-Bauer S. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. Cancers (Basel). 2019 Feb 18;11(2):238. doi: 10.3390/cancers11020238. — View Citation

Klein JP & Moeschberger ML (2010). Survival analysis: Techniques for censored and truncated data (2. ed., corr. 3. print). Springer.

Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, Harbeck N. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res. 2022 Sep 2;24(1):58. doi: 10.1186/s13058-022-01552-w. — View Citation

Lee HJ, Lee JJ, Song IH, Park IA, Kang J, Yu JH, Ahn JH, Gong G. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat. 2015 Jun;151(3):619-27. doi: 10.1007/s10549-015-3438-8. Epub 2015 May 26. — View Citation

Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4. — View Citation

Llombart-Cussac A, Cortes J, Pare L, Galvan P, Bermejo B, Martinez N, Vidal M, Pernas S, Lopez R, Munoz M, Nuciforo P, Morales S, Oliveira M, de la Pena L, Pelaez A, Prat A. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24. — View Citation

Loi S, Schmid P, Aktan G, Karantza V & Salgado R (2019). 4O Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. Annals of Oncology

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158. Erratum In: Ann Oncol. 2022 Jul;33(7):743-744. — View Citation

Loibl S, Werutsky G, Nekljudova V, Seiler S, Blohmer JU, Denkert C, Hanusch C, Huober JB, Jackisch C, Kummel S, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Von Minckwitz G & Furlanetto J (2017). Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. Journal of Clinical Oncology

Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5. — View Citation

Matsushita M, Kawaguchi M. Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy. J Oncol. 2018 Oct 25;2018:8653489. doi: 10.1155/2018/8653489. eCollection 2018. — View Citation

Nuciforo P, Pascual T, Cortes J, Llombart-Cussac A, Fasani R, Pare L, Oliveira M, Galvan P, Martinez N, Bermejo B, Vidal M, Pernas S, Lopez R, Munoz M, Garau I, Manso L, Alarcon J, Martinez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647. — View Citation

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. — View Citation

Park MM, Ebel JJ, Zhao W, Zynger DL. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment. Breast J. 2014 Jan-Feb;20(1):37-45. doi: 10.1111/tbj.12223. Epub 2013 Nov 22. — View Citation

Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012 Mar 15;118(6):1498-506. doi: 10.1002/cncr.26431. Epub 2011 Aug 11. — View Citation

Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, Ranade K. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res. 2018 Dec 15;24(24):6212-6222. doi: 10.1158/1078-0432.CCR-18-0386. Epub 2018 Aug 9. — View Citation

Royston P & Sauerbrei W (2008). Multivariable Model-Building. John Wiley & Sons, Ltd.

Saliou A, Bidard FC, Lantz O, Stern MH, Vincent-Salomon A, Proudhon C, Pierga JY. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. Expert Rev Mol Diagn. 2016;16(1):39-50. doi: 10.1586/14737159.2016.1121100. Epub 2015 Dec 9. — View Citation

Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 1;121(19):3422-7. doi: 10.1002/cncr.29572. Epub 2015 Aug 17. — View Citation

Schmid P, Cortés J, Dent R, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C, Park YH & Hui R (2019). KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Annals of Oncology

Schmid P. ESMO 2018 presidential symposium-IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer. ESMO Open. 2018 Oct 20;3(6):e000453. doi: 10.1136/esmoopen-2018-000453. eCollection 2018. No abstract available. — View Citation

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172. — View Citation

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. — View Citation

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013 Jul;24(7):1813-1821. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27. — View Citation

Sokolenko AP, Imyanitov EN. Molecular Tests for the Choice of Cancer Therapy. Curr Pharm Des. 2017;23(32):4794-4806. doi: 10.2174/1381612823666170719110125. — View Citation

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. doi: 10.1073/pnas.191367098. — View Citation

Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018 Oct 9;10:4333-4347. doi: 10.2147/CMAR.S174435. eCollection 2018. — View Citation

Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15;13(6):1757-61. doi: 10.1158/1078-0432.CCR-06-2599. — View Citation

Tibshirani R (1996). Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society. Series B (Methodological)

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kummel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynakologische Onkologie-Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):345-356. doi: 10.1016/S1470-2045(15)00542-2. Epub 2016 Feb 8. Erratum In: Lancet Oncol. 2016 Jul;17 (7):e270. — View Citation

Yang B, Chou J, Tao Y, Wu D, Wu X, Li X, Li Y, Chu Y, Tang F, Shi Y, Ma L, Zhou T, Kaufmann W, Carey LA, Wu J, Hu Z. An assessment of prognostic immunity markers in breast cancer. NPJ Breast Cancer. 2018 Oct 29;4:35. doi: 10.1038/s41523-018-0088-0. eCollection 2018. — View Citation

Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May;25(5):1004-11. doi: 10.1093/annonc/mdu053. Epub 2014 Feb 20. — View Citation

* Note: There are 51 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response (ypT0/is, ypN0)	Pathological Complete Response defined as no residual invasive tumor cells in the breast and in the lymph nodes (ypT0/is, ypN0)	after 29-30 weeks in Arm A and after 27-28 weeks in Arm B.
Secondary	Safety Measures	Safety (incidence, relationship, seriousness, and severity of all AEs, SAEs, AESIs coded by medical dictionary for regulatory activities (MedDRA), summarized by Preferred Term and System Organ Class and graded according to common terminology criteria of adverse events (CTCAE V5.0)	from date of randomization up to 59 months
Secondary	Pathological Complete Response (ypT0/is, ypN0) (ER/PR expression of <1%)	Pathological complete response defined as no residual invasive tumor cells in the breast and in the lymph nodes (ypT0/is, ypN0) in patients with an ER/PR expression of <1% and an ER/PR expression of 1% to 10%.	after 29-30 weeks in Arm A and after 27-28 weeks in Arm B
Secondary	Pathological Complete Response (ypT0, ypN0)	Pathological complete response defined as no tumor cells (invasive and no non-invasive) in the breast but also in the lymph nodes (ypN0, ypT0)	after 29-30 weeks in Arm A and after 27-28 weeks in Arm B.
Secondary	Near Pathological Complete Response (Near pCR)	Near pCR defined as residual tumor <5 mm in the breast irrespective of in situ and lymph nodes status	after 29-30 weeks in Arm A and after 27-28 weeks in Arm B.
Secondary	Pathological Complete Response (no invasive tumor)	Pathological Complete Response defined as no invasive tumor in the breast, irrespective of lymph node status	after 29-30 weeks in Arm A and after 27-28 weeks in Arm B.
Secondary	Decrease of Ki-67 expression as continuous predictor	Decrease of Ki-67 expression versus baseline after 14/28 days (+/- 2 days) of treatment as continuous predictor	after 14/28 days (+/- 2 days) of treatment
Secondary	Tumor-infiltrating lymphocytes (TILs)	TILs after 14/28 days (+/- 2 days) of treatment as continuous predictor	after 14/28 days (+/- 2 days) of treatment
Secondary	Complete Cell Cycle Arrest (CCCA)	CCCA: Ki-67 expression = 2.7% after 14/28 days (+/- 2 days) of treatment	after 14/28 days (+/- 2 days) of treatment
Secondary	Low cellularity	Low cellularity: < 500 tumor cells after 14/28 days (+/- 2 days) of treatment	after 14/28 days (+/- 2 days) of treatment
Secondary	Decrease of Ki-67 expression	Decrease of Ki-67 expression versus baseline by 30% or more after 14/28 days (+/- 2 days) of treatment	after 14/28 days (+/- 2 days) of treatment
Secondary	Tumor-infiltrating lymphocytes (TILs) = 60%	TILs = 60% after 14/28 days (+/- 2 days) of treatment	after 14/28 days (+/- 2 days) of treatment
Secondary	Combined early response	Combined early response defined by; CCCA (Ki-67 expression < 2.7%) or; low cellularity or; decrease of Ki-67 expression (versus baseline) by 30% or more or; TILs = 60%	after 14/28 days (+/- 2 days) of treatment
Secondary	Disease free survival (DFS)	Disease free survival (DFS) defined as time from the first date of no disease [i.e. date of surgery] to the first occurrence of disease recurrence or death from any cause	from randomization up to 59 months until date of occurrence of no disease to the first occurrence of disease recurrence or death from any cause
Secondary	Overall survival (OS)	Overall survival (OS) defined as length of time from randomization to death from any cause	from randomization up to 59 months until date of death from any cause
Secondary	Event free survival (EFS)	Event free survival (EFS) defined as length of time after randomization till death from any cause, failure to achieve remission after induction therapy, relapse in any site, or second malignancy	from randomization up to 59 months until date of death from any cause, failure to achieve remission after induction therapy, relapse in any site, or second malignancy